CompBrief BY VELARION

Companies Syros Pharmaceuticals, Inc.

Syros Pharmaceuticals CEO salary & total pay, FY2023: $1M

Syros Pharmaceuticals (SYRS) CEO salary, fiscal 2023: Conley Chee was paid a salary of $479,092 and $1,041,697 in total compensation. Free brief. Every figure links to the company’s own filing.

Syros Pharmaceuticals, Inc. no longer files a proxy statement; its last pay data is FY2023.

All products and prices

Conley Chee's complete compensation dossier

A PDF and a CSV sent to your email: Conley Chee's pay in every fiscal year Syros Pharmaceuticals, Inc. reported it, line by line, with Conley Chee's equity grants and Syros Pharmaceuticals, Inc.'s disclosed peer group where the company discloses them. Every row is cited to its filing.

One-time report. No refunds.

See an example →
CEO total pay$1,041,697CEO Conley Chee · source
Say-on-pay support97.94%Latest vote · source

CEO pay, last three years

  • $3,487,880FY2022
  • $1,041,697FY2023

CEO total pay was $1,041,697 in fiscal 2023 (Conley Chee), down from $3,487,880 in fiscal 2022 (Nancy Simonian, the CEO that year).

FY2023: salary $479,092 · bonus $0 · stock awards $369,460 · option awards $0

Executives and directors

Frequently asked questions

Who was the highest-paid executive at Syros Pharmaceuticals, Inc. in fiscal 2023?
As disclosed, Nancy Simonian (Former President & Chief Executive Officer) was the highest-paid executive at Syros Pharmaceuticals, Inc. in fiscal 2023, with total compensation of $1,436,782.
How did shareholders vote on Syros Pharmaceuticals, Inc.'s executive compensation?
As disclosed, 97.94% of shareholders supported Syros Pharmaceuticals, Inc.'s executive compensation in the latest say-on-pay vote.
How much does Syros Pharmaceuticals, Inc. spend in total on board compensation for fiscal 2023?
As disclosed, Syros Pharmaceuticals, Inc. reported total board compensation of $534,570 for fiscal 2023.

Answers are drawn only from the figures disclosed in this brief and cited to their location in the source filing. Where a figure required for an answer is not disclosed, that is stated rather than estimated.

Full detail

Every table from the filing. Open any section.

Summary compensation table
Named executive officerSalaryBonusStock awardsOption awardsNon-equity incentivePension / NQDCAll otherTotal
Nancy Simonian$635,385$0$477,174$0$318,986$0$5,237$1,436,782
Former President & Chief Executive Officer
Conley Chee479,0920369,4600192,45506901,041,697
President & Chief Executive Officer
Eric Olson409,7910140,700000385,277935,768
Former Chief Scientific Officer
David Roth516,1540160,8000197,60001,980876,534
Chief Medical Officer
Jason Haas485,1850160,8000185,74401,290833,019
Chief Financial Officer

A dash means the company reported no figure in that column; 0 means it reported zero. Figures are as printed in the filing, without adjustment.

Three-year trend — total compensation per named executive

Named executive officerFY2023 totalFY2022 totalFY2021 totalΔ FY2022→2023
Nancy Simonian$1,436,782$3,487,880—↓ −2,051,098
Conley Chee1,041,697———
Eric Olson935,7681,668,669—↓ −732,901
David Roth876,5341,759,093—↓ −882,559
Jason Haas833,0191,416,010—↓ −582,991

Prior-year totals as disclosed in the corresponding proxy; deltas are computed values with the derivation shown in the register.

Incentive-plan design — the Compensation Discussion & Analysis

The company aims to reward value creation for stockholders and attract, motivate, and retain executive officers by aligning their interests with those of stockholders through a mix of short-term and long-term performance-based incentives. The compensation committee considers market comparables, individual and corporate performance, and the desire to foster long-term commitment while managing dilution.

CEO STI target (% of salary)—
CEO LTI target (% of salary)—
Independent consultantCompensia Inc.
Clawback policytrue
Anti-hedgingtrue
Anti-pledgingtrue
Equity grants and outstanding awards

No plan-based awards are on file for this fiscal year.

Outstanding equity awards at fiscal year-end 2023

ExecutiveAwardExercisableShares unvestedExercise priceMarket value unvested
Conley CheeOption20,24815,75248.1—
Conley CheeOption4,5805,42015.9—
Conley CheeOption22,25022,2506.73—
Conley CheeRSU—6,000—46,740
Conley CheeRSU—17,000—132,430
Conley CheeRSU—35,000—272,650
Conley CheeRSU—86,000—669,940
Conley CheePSU—35,000—272,650
Conley CheePSU—86,000—669,940
David RothOption9,00339675.4—
David RothOption8,4283,471114.1—
David RothOption5,7246,77515.9—
David RothOption24,87524,8756.73—
David RothRSU—6,000—46,740
David RothRSU—20,000—155,800
David RothRSU—18,875—147,036
David RothRSU—40,000—311,600
David RothPSU—40,000—311,600
David RothOption22,364—90.8—
David RothOption6,349—109—
David RothOption7,499—109—
David RothOption7,499—67.1—
Eric OlsonOption453—13.88—
Eric OlsonOption3,477—30.38—
Eric OlsonOption2,584—30.4—
Eric OlsonOption6,349—109—
Eric OlsonOption7,499—109—
Eric OlsonOption7,499—67.1—
Eric OlsonOption8,415—75.4—
Eric OlsonOption6,069—114.1—
Eric OlsonOption3,955—15.9—
Jason HaasOption40,61834,38245.4—
Jason HaasOption5,7256,77515.9—
Jason HaasOption24,87524,8756.73—
Jason HaasRSU—6,000—46,740
Jason HaasRSU—18,875—147,036
Jason HaasRSU—40,000—311,600
Jason HaasPSU—40,000—311,600
Nancy SimonianOption17,18520,31415.9—
Nancy SimonianOption57,50057,5006.73—
Nancy SimonianRSU—18,000—140,220
Nancy SimonianRSU—40,000—311,600
Nancy SimonianRSU—40,125—312,574
Nancy SimonianRSU—118,700—924,673
Nancy SimonianPSU—118,700—924,673
Nancy SimonianOption3,766—30.4—
Nancy SimonianOption3,483—30.4—
Nancy SimonianOption2,152—30.4—
Nancy SimonianOption7,916—85.13—
Nancy SimonianOption28,500—67.1—
Director compensation
DirectorCash feesStock awardsOption awardsNon-equity incentiveAll otherTotal
Peter WirthIndependent$80,000$14,800$15,604—$0$110,404
Marsha H. FanucciIndependent54,37514,80015,604—084,779
S. Gail EckhardtIndependent52,00014,80015,604—082,404
Richard A. YoungIndependent51,75014,80015,604—082,154
Deborah DunsireIndependent48,67014,80015,604—079,074
Andrew M. OhIndependent48,12514,80015,604—078,154
Timothy C. TysonIndependent45,62514,80015,604—076,029
Mark J. AllesIndependent35,62514,80015,604—066,029

Board fee structure and ownership guideline

Annual cash retainer$40,000
Annual equity retainer—
Per board meeting fee—
Committee chair fees (audit / comp / nom-gov)15,000 / 10,000 / 8,000
Stock ownership guideline—

Total cost of the board

ComponentFY2023
Cash retainers and fees$416,170
Equity awards (grant-date value)$118,400
All other compensation$0
Total cost of the board$534,570

Computed as the sum of the director compensation table rows above; inputs and formula shown in the register.

Peer group, and who names Syros Pharmaceuticals as a peer

Companies that benchmark against SYRS

4 companies name SYRS as a compensation peer

The list of companies that name SYRS as a peer is temporarily unavailable — recheck shortly.

Chief executive pay against the peer group

Most recent fiscal-year chief executive compensation at each disclosed peer, taken from that company’s own proxy statement.

RankCompanyFYChief executiveSalaryStock awardsOption awardsNon-equity incentiveTotal
1Syros Pharmaceuticals, Inc.2023Conley Chee$479,092$369,460$0$192,455$1,041,697

Each peer’s compensation is from its most recently filed proxy; fiscal years differ by company. Each peer’s figures come from its own filings; the subject company is highlighted. Peers whose chief executive compensation is outside our coverage universe are stated as such, never left blank.

Say-on-pay history and pay ratio
Meeting yearMeeting dateForAgainstAbstainSupportOutcome
20242024-06-0517,127,081359,88320,39797.94%Passed
20232023-06-018,112,3981,252,885100,12786.62%Passed
20222022-06-0138,974,4151,485,752132,76596.33%Passed

Rows are labeled by annual-meeting year, with the meeting date beside each; the vote held in a given year acts on the prior fiscal year’s compensation.

Say-on-pay — history, company’s computation

Meeting yearMeeting dateApproval — company’s computation
20242024-06-0597.94%a
20232023-06-0186.62%b
20222022-06-0196.33%c

a. Voting standard not stated in the filing.

b. Voting standard not stated in the filing.

c. Voting standard not stated in the filing.

Approval percentages are the company’s own reported computations under its own stated standard, not recomputed by Velarion. Where a company does not state a standard, none is assumed.

Insider trades since the proxy

Every insider equity transaction reported on Form 4 after the 2023 proxy statement — acquisitions, dispositions, exercises, and withholdings — and therefore not reflected in any table in that document.

InsiderRoleTransaction dateCodeSharesPriceValueSecuritySource
Srinivas AkkarajuDirector2024-06-01D4,000$0$0Derivative, Class A CommonForm 4 ↗
Srinivas AkkarajuDirector2024-06-01A4,000——CommonForm 4 ↗
Deborah DunsireDirector2024-06-01D4,00000Derivative, Class A CommonForm 4 ↗
Deborah DunsireDirector2024-06-01A4,000——CommonForm 4 ↗
Srinivas AkkarajuDirector2024-06-05A4,00000Derivative, Class A CommonForm 4 ↗
Srinivas AkkarajuDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Peter WirthDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Peter WirthDirector2024-06-05A4,00000CommonForm 4 ↗
Marsha H. FanucciDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Marsha H. FanucciDirector2024-06-05A4,00000CommonForm 4 ↗
Andrew M. OhDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Andrew M. OhDirector2024-06-05A4,00000CommonForm 4 ↗
S. Gail EckhardtDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
S. Gail EckhardtDirector2024-06-05A4,00000CommonForm 4 ↗
Deborah DunsireDirector2024-06-05A4,00000Derivative, Class A CommonForm 4 ↗
Deborah DunsireDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Timothy C. TysonDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Timothy C. TysonDirector2024-06-05A4,00000CommonForm 4 ↗
Richard A. YoungDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Richard A. YoungDirector2024-06-05A4,00000CommonForm 4 ↗
Nancy SimonianDirector2024-06-05A6,00000Derivative, Class A CommonForm 4 ↗
Nancy SimonianDirector2024-06-05A4,00000CommonForm 4 ↗
Richard A. YoungDirector2024-06-28D34,8375178,365CommonForm 4 ↗
Conley CheeDirector2024-09-10A50,000275,260CommonForm 4 ↗
Jason HaasChief Financial Officer2024-09-10A35,363254,788CommonForm 4 ↗
Conley CheeDirector2024-09-11A50,000285,420CommonForm 4 ↗
Jason HaasChief Financial Officer2024-09-11A19,293230,446CommonForm 4 ↗
Jason HaasChief Financial Officer2024-09-12A45,344276,006CommonForm 4 ↗
Richard A. YoungDirector2024-09-16D2,66700Derivative, Class A CommonForm 4 ↗
Richard A. YoungDirector2024-09-16A2,667——CommonForm 4 ↗
Srinivas AkkarajuDirector2024-09-16D2,66700Derivative, Class A CommonForm 4 ↗
Srinivas AkkarajuDirector2024-09-16A2,667——CommonForm 4 ↗
Gerald E. QuirkChief Legal & Compliance Offic2024-09-30D10,00000Derivative, Class A CommonForm 4 ↗
Gerald E. QuirkChief Legal & Compliance Offic2024-09-30D3,10026,510CommonForm 4 ↗
Gerald E. QuirkChief Legal & Compliance Offic2024-09-30A10,000——CommonForm 4 ↗
Kristin StephensChief Development Officer2024-10-31D17,00000Derivative, Class A CommonForm 4 ↗
Kristin StephensChief Development Officer2024-10-31D6,104212,757CommonForm 4 ↗
Kristin StephensChief Development Officer2024-10-31A17,000——CommonForm 4 ↗
Conley CheeDirector2024-10-31D17,00000Derivative, Class A CommonForm 4 ↗
Conley CheeDirector2024-10-31D8,707218,198CommonForm 4 ↗
Conley CheeDirector2024-10-31A17,000——CommonForm 4 ↗
Jason HaasChief Financial Officer2024-10-31D18,87500Derivative, Class A CommonForm 4 ↗
Jason HaasChief Financial Officer2024-10-31D5,624211,754CommonForm 4 ↗
Jason HaasChief Financial Officer2024-10-31A18,875——CommonForm 4 ↗
David RothChief Medical Officer2024-10-31D18,87500Derivative, Class A CommonForm 4 ↗
David RothChief Medical Officer2024-10-31D6,776214,162CommonForm 4 ↗
David RothChief Medical Officer2024-10-31A18,875——CommonForm 4 ↗
Nancy SimonianDirector2024-10-31D40,12500Derivative, Class A CommonForm 4 ↗
Nancy SimonianDirector2024-10-31A40,125——CommonForm 4 ↗
Jason HaasChief Financial Officer2024-11-18D137,803028,980CommonForm 4 ↗
Conley CheeDirector2024-11-18D134,797026,932CommonForm 4 ↗
David RothChief Medical Officer2024-11-18D12,09902,382CommonForm 4 ↗
Kristin StephensChief Development Officer2024-11-18D36,13307,949CommonForm 4 ↗
Gerald E. QuirkChief Legal & Compliance Offic2024-11-19D46,657010,321CommonForm 4 ↗
Nancy SimonianDirector2024-11-25D134,713035,739CommonForm 4 ↗
Nancy SimonianDirector2024-12-02D37,070010,016CommonForm 4 ↗

Transaction codes per Form 4: A acquisition · S open-market sale · F tax withholding · M option exercise · G gift. Value = shares × price as reported. Dividend-equivalent and fractional-share accrual rows (derivative Class A, under $10,000 and under 2,000 shares) are aggregated per date; every row appears in full below.

Sources (75 citations)

Each figure is listed with the filing it comes from, where it appears in that filing, and the value as printed. Any figure can be independently confirmed against the source.

  • Section 01, Nancy Simonian. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,436,782. View filing ↗
  • Section 01, Conley Chee. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 1,041,697. View filing ↗
  • Section 01, Eric Olson. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 935,768. View filing ↗
  • Section 01, David Roth. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 876,534. View filing ↗
  • Section 01, Jason Haas. 10-K, filed 2024-04-23. Section “Executive Compensation”. As printed: 833,019. View filing ↗
  • Section 08, Peter Wirth. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 110,404. View filing ↗
  • Section 08, Marsha H. Fanucci. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 84,779. View filing ↗
  • Section 08, S. Gail Eckhardt. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,404. View filing ↗
  • Section 08, Richard A. Young. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 82,154. View filing ↗
  • Section 08, Deborah Dunsire. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 79,074. View filing ↗
  • Section 08, Andrew M. Oh. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 78,154. View filing ↗
  • Section 08, Timothy C. Tyson. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 76,029. View filing ↗
  • Section 08, Mark J. Alles. 10-K, filed 2024-04-23. Section “Director Compensation”. As printed: 66,029. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Deborah Dunsire 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Deborah Dunsire 2024-06-01. Form 4, filed 2024-06-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Peter Wirth 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Peter Wirth 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Marsha H. Fanucci 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Marsha H. Fanucci 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew M. Oh 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Andrew M. Oh 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, S. Gail Eckhardt 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, S. Gail Eckhardt 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Deborah Dunsire 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Deborah Dunsire 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Timothy C. Tyson 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Timothy C. Tyson 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Young 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Young 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-06-05. Form 4, filed 2024-06-07. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Young 2024-06-28. Form 4, filed 2024-07-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-09-10. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-09-10. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-09-11. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-09-11. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-09-12. Form 4, filed 2024-09-12. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Young 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Richard A. Young 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Srinivas Akkaraju 2024-09-16. Form 4, filed 2024-09-18. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gerald E. Quirk 2024-09-30. Form 4, filed 2024-10-02. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kristin Stephens 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Roth 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-10-31. Form 4, filed 2024-11-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Jason Haas 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Conley Chee 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, David Roth 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Kristin Stephens 2024-11-18. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Gerald E. Quirk 2024-11-19. Form 4, filed 2024-11-20. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-11-25. Form 4, filed 2024-11-27. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 02, Nancy Simonian 2024-12-02. Form 4, filed 2024-12-04. Insider equity transaction reported since the proxy statement. View filing ↗
  • Section 06, 2024 vote. Form 8-K, filed 2024-06-06. Item 5.07 · say-on-pay result. As reported: 97.94% (votes for as printed: 17,127,081). View filing ↗
  • Section 06, 2023 vote. Form 8-K, filed 2023-06-02. Item 5.07 · say-on-pay result. As reported: 86.62% (votes for as printed: 8,112,398). View filing ↗
  • Section 06, 2022 vote. Form 8-K, filed 2022-06-07. Item 5.07 · say-on-pay result. As reported: 96.33% (votes for as printed: 38,974,415). View filing ↗
  • Section 01 trend, Δ column (computed). Computed. Δ = current-FY total − prior-FY total per named officer.
  • Section 09b board cost (computed). Computed. Cash 416,170 + equity 118,400 + all other 0 = 534,570, summed across the director compensation table rows.
  • Syros Pharmaceuticals, Inc. (subject), Section 10b CEO total. 10-K, filed 2024-04-23. CEO total compensation as printed in Syros Pharmaceuticals, Inc.'s own proxy. As printed: 1,041,697. View filing ↗